News | Cardiac Imaging | July 03, 2018

Study finds combining coronary CT angiography with SPECT provides accurate information on both stenosis and perfusion

Cardiac Hybrid Imaging an Effective Tool for Predicting Heart Attacks

July 3, 2018 — Cardiac hybrid imaging with computed tomography (CT) and nuclear stress testing is an excellent long-term predictor of adverse cardiac events like heart attacks in patients being evaluated for coronary artery disease, according to a study published in the journal Radiology.

Coronary artery disease is a leading cause of death and disability worldwide. Invasive coronary angiography (ICA) is considered the gold standard for determining the percent of stenosis, or narrowing, due to plaque in a coronary artery. However, the degree of stenosis on ICA is not always an accurate predictor of heart attack risk because it gives no information on perfusion, or the flow of blood into the heart muscle. Inadequate perfusion, also known as ischemia, is a potential danger to the patient.

“In lesions with less than 50 percent narrowing, one in five lesions still produce an ischemia,” said study coauthor Philipp A. Kaufmann, M.D., professor and chair of nuclear medicine, and director of cardiac imaging at University Hospital Zurich in Switzerland.

Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion. The approach has shown promise in studies focusing on short-term observations, but information is lacking on long-term outcomes.

The research team looked at 428 patients who underwent hybrid imaging. During a median follow-up of 6.8 years, a total of 160 major adverse cardiac events, including 45 deaths, were observed in the final study population. Patients with matched findings — stenosis of 50 percent or more on CCTA with evidence of ischemia on SPECT in the area of the heart to which the blocked vessel was supplying blood — had more than five times the risk of adverse events than those with normal findings. Patients with unmatched findings, or evidence of ischemia but not in the area of the heart being fed by the stenotic artery, had three times the risk. Major adverse cardiac event rates were 21.8 percent for matched findings and 9 percent for unmatched — considerably higher than the 2.4 percent rate for normal findings.

The results show that cardiac hybrid imaging is an excellent long-term predictor of adverse cardiac events in patients evaluated for coronary artery disease. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.

“In patients with multiple lesions or complex coronary anatomy, it is, in many cases, very difficult to correctly identify the culprit lesion,” he said. “In a previous multicenter trial, with hybrid imaging we were able to see that about one in five patients should be revascularized in another coronary artery than originally planned. The present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.”

The study supports CCTA use for an initial, noninvasive evaluation of patients with known or suspected stable coronary artery disease. No additional imaging would be necessary if the results were normal. If a lesion was evident, then clinicians could employ a nuclear scan to assess ischemia and take advantage of both modalities by fusing the results together to make a hybrid image.

“The strategy of direct referral to invasive coronary angiography without noninvasive imaging is obsolete,” Kaufmann said. “Even after documenting coronary artery disease with coronary CT angiography, we need further noninvasive evaluation before deciding upon revascularization versus medication.”

The researchers hope to run a trial to show that hybrid imaging can have a positive impact on patient outcomes. They are also looking at what they call “triple hybrid” imaging, which combines the CCTA/SPECT hybrid with information on coronary artery shear stress. The shear stress information could help identify lesions that do not yet have an impact on ischemia but will in the future.

For more information: www.pubs.rsna.org/journal/radiology

Reference

Kaufmann P.A., Pazhenkottil A.P., Benz D.C., et al. “Hybrid SPECT Perfusion Imaging and Coronary CT Angiography: Long-Term Prognostic Value for Cardiovascular Outcomes,” Radiology, July 3, 2018. https://doi.org/10.1148/radiol.2018171303

 


Related Content

News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiology Business

April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc., GE HealthCare ...

Time April 02, 2024
arrow
News | Radiation Oncology

April 2, 2024 — In a 10-center study, microwave ablation offered progression free survival rates and fewer complications ...

Time April 02, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiation Therapy

March 28, 2024 — RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software ...

Time March 28, 2024
arrow
Subscribe Now